Le Lézard
Classified in: Health
Subjects: NPT, AVO

PCMA Statement on the CMS Medicare Part D Proposed Rule


WASHINGTON, Nov. 17, 2017 /PRNewswire-USNewswire/ -- The Pharmaceutical Care Management Association (PCMA) released the following statement on the Centers for Medicare & Medicaid Services' (CMS) Medicare Parts C and D proposed rule:

"Since its inception, Medicare Part D has been a bright spot in American health care, offering generous, affordable coverage to more than 42 million beneficiaries. The program has routinely delivered low premiums and high satisfaction for the nation's seniors and disabled.

While we are still reviewing the draft proposed rule, we are initially encouraged by provisions that promote the use of lower cost generics and biosimilars and make it harder for at-risk patients to go 'drugstore shopping' for opioids.

We are also encouraged CMS continues to allow plan sponsors the option to use the price concessions they negotiate with manufacturers and drugstores to reduce premiums and other costs.  According to CMS, requiring plans to estimate and apply manufacturer rebates at the point-of-sale would raise premiums by up to $28 billion and taxpayer costs by up to $82 billion over the next decade.  Such a requirement would also create a windfall for drugmakers, who would pay up to $29 billion less in donut-hole discounts.

If pharmacy price concessions were also required to be applied at the point-of-sale, taxpayer costs would increase by an additional $16.6 billion over the next decade, while premiums would rise by an additional $5.7 billion, according to CMS.

Notably, the proposed rule addresses both the point-of-sale rebates and direct and indirect remuneration (DIR) issues through a Request for Information (RFI) rather than a requirement.

At the same time, new any willing pharmacy requirements outlined in the proposed rule could put at risk the choice and affordability of preferred pharmacy plans ? the most popular and widely chosen options in Part D.   Protecting the stability of those plan options should be a top priority for regulators."

PCMA is the national association representing America's pharmacy benefit managers (PBMs). PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, Medicaid plans, and others.

 

SOURCE Pharmaceutical Care Management Association


These press releases may also interest you

at 19:15
Denver nonprofit Justice Necessary unveils data from its latest study on teen period poverty in Colorado, shedding light on a deeply concerning issue. The findings of this study underscore the urgent need for action to address the need for teens to...

at 19:05
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched...

at 18:00
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM. MamaLift Plus is the first prescription digital therapeutic for the treatment of postpartum depression (PPD), a...

at 17:45
BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30th ? May 2nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent,...

at 17:44
United Breast Cancer Foundation (UBCF) is proud to host a heartfelt event dedicated to honor the memory of Audrey Beverly Christy Mastroianni, a remarkable Rhode Island woman who bravely battled breast cancer. The "Gifts of Comfort and Hope" Mattress...

at 17:31
DRI Healthcare Trust (the "Trust") announces the closing of its previously announced preferred securities refinancing, whereby its US$114,760,000 aggregate principal amount of Series A and Series B preferred securities and 6,369,180 warrants were...



News published on and distributed by: